PPARγ activation in human endothelial cells increases plasminogen activator inhibitor type-1 expression: PPARγ as a potential mediator in vascular disease

Arteriosclerosis, Thrombosis, and Vascular Biology

Volumn 19, Issue 3, 1999, Pages 546-551

  Marx, Nikolaus ^a   Bourcier, Todd ^a   Sukhova, Galina K ^a   Libby, Peter ^a   Plutzky, Jorge ^a,b  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

^b HARVARD MEDICAL SCHOOL   (United States)

Author keywords

15 deoxy ( 12,14) prostaglandin J2; Atherosclerosis; Endothelium; Peroxisomal proliferator activated receptor; Plasminogen activator inhibitor 1

Indexed keywords

15 DEOXY DELTA 12,14 PROSTAGLANDIN J2; CORIOLIC ACID; DIMORPHECOLIC ACID; DNA; LUCIFERASE; MESSENGER RNA; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR; PLASMINOGEN ACTIVATOR INHIBITOR 1; PROSTAGLANDIN DERIVATIVE; TRANSCRIPTION FACTOR; UNCLASSIFIED DRUG; 15 DEOXY DELTA(12,14) PROSTAGLANDIN J2; 15-DEOXY-DELTA(12,14)-PROSTAGLANDIN J2; CELL RECEPTOR; DNA BINDING PROTEIN; DRUG DERIVATIVE; PROSTAGLANDIN D2;

ANIMAL CELL; ARTICLE; ATHEROSCLEROSIS; CAROTID ARTERY; CATTLE; CONTROLLED STUDY; DNA RESPONSIVE ELEMENT; ENDOTHELIUM CELL; FIBROBLAST; GENE EXPRESSION; GENETIC TRANSFECTION; HUMAN; HUMAN CELL; HUMAN TISSUE; MEDIATOR; NONHUMAN; OBESITY; PRIORITY JOURNAL; SAPHENOUS VEIN; VASCULAR DISEASE; ADIPOSE TISSUE; ANIMAL; ARTERIOSCLEROSIS; BLOOD CLOTTING; CELL CULTURE; CYTOLOGY; DOSE RESPONSE; DRUG EFFECT; ENZYME ACTIVATION; GENETICS; METABOLISM; PHYSIOLOGY; REPORTER GENE; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SIGNAL TRANSDUCTION; VASCULAR ENDOTHELIUM; VASCULARIZATION;

ADIPOSE TISSUE; ANIMALS; ARTERIOSCLEROSIS; BLOOD COAGULATION; CAROTID ARTERIES; CATTLE; CELLS, CULTURED; DNA-BINDING PROTEINS; DOSE-RESPONSE RELATIONSHIP, DRUG; ENDOTHELIUM, VASCULAR; ENZYME ACTIVATION; FIBROBLASTS; GENE EXPRESSION; GENES, REPORTER; HUMANS; LUCIFERASES; PLASMINOGEN ACTIVATOR INHIBITOR 1; PROSTAGLANDIN D2; RECEPTORS, CYTOPLASMIC AND NUCLEAR; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; SAPHENOUS VEIN; SIGNAL TRANSDUCTION; TRANSCRIPTION FACTORS; TRANSFECTION;

EID: 0032587328     PISSN: 10795642     EISSN: None     Source Type: Journal    
DOI: 10.1161/01.ATV.19.3.546     Document Type: Article

References (44)

1. Martin N, Jamieson A, Tuffin D. The effect of interleukin-4 on tumor necrosis factor-α induced expression of tissue factor and plasminogen activator inhibitor-1 in human umbilical vein endothelial cells. Thromb Haemost. 1993;70:1037-1042.
2. Loskutoff DJ, Samad F. The adipocyte and hemostatic balance in obesity studies of PAI-1. Arterioscler Thromb Vasc Biol. 1998;18:1-6.
3. Hamsten A, Faire U, Walldius G, Dahlen G, Szamosi A, Landou C, Blombaeck M, Wiman B. Plasminogen activator inhibitor in plasma: risk factor for recurrent myocardial infarction. Lancet. 1987;2:3-9.
4. Cortarello M, Cofrancesco E, Boschetti C, Mussoni L, Donati M, Tremoli E, Pozzoli E, Turri P. Increased fibrin turnover and high PAI-1 activity as predictors of ischemic events in atherosclerotic patients. Arterioscler Thromb. 1993;13:1412-1417.
5. Wiman B, Hamsten A. Impaired fibrinolysis and risk of thromboembolism. Prog Cardiovasc Dis. 1991;34:179-192.
6. Vaughan D, Lazos S, Tong K. Angiotensin n regulates the expression of plasminogen activator inhibitor-1 in cultured endothelial cells: a potential link between the renin-angiotensin system and thrombosis. J Clin Invest. 1995; 95:995-1001.
7. Handt S, Jerome W, Tietze L, Hantgan R. Plasminogen activator inhibitor-1 secretion of endothelial cells increases fibrinolytic resistance of an in vitro fibrin clot: evidence for a key role of endothelial cells in thrombolytic resistance. Blood. 1996;87:4204-4213.
8. Gallicchio M, Hufnagl P, Wojta J, Tipping P. IFN-γ inhibits thrombin-and endotoxin-induced plasminogen activator inhibitor type 1 in human endothelial cells. J Immunol. 1996;157:2610-2617.
9. van Hinsbergh V, Kooistra T, van den Berg E, Princen H, Fiers W, Emeis J. Tumor necrosis factor increases the production of plasminogen activator inhibitor in human endothelial cells in vitro and in rats in vivo. Blood. 1988;72:1467-1473.
10. Slivka SR, Loskutoff DJ. Platelets stimulate endothelial cells to synthesize type 1 plasminogen activator inhibitor: evaluation of the role of transforming growth factor-β. Blood. 1991;77:1013-1019.
11. Latron Y, Chautan M, Anfosso F, Alessi M, Nalbone G, Lafont H, Juhan-Vague I. Stimulating effect of oxidized low density lipoproteins on plasminogen activator inhibitor-1 synthesis by endothelial cells. Arterioscler Thromb. 1991;11:1821-1829.
12. Arts J, Kockx M, Princen H, Kooistra T. Studies on the mechanism of fibrate-inhibited expression of plasminogen activator inhibitor-1 in cultured hepatocytes from cynomolgus monkey. Arterioscler Thromb Vasc Biol. 1997;17:26-32.
13. Alessi M, Peiretti F, Morange P, Henry M, Nalbone G, Juhan-Vague I. Production of plasminogen activator inhibitor 1 by human adipose tissue: possible link between visceral fat accumulation and vascular disease. Diabetes. 1997;46:860-867.
14. Braissant O, Foufelle F, Scotto C, Dauca M, Wahli W. Differential expression of peroxisome proliferator-activated receptors (PPARs): tissue distribution of PPAR-α, -β, and-γ in the adult rat. Endocrinology. 1996;137: 354-366.
15. Greene M, Blumberg B, McBride O, Kronquist K, Kwan K, Hsieh L, Greene G. Nimer S. Isolation of the human peroxisome proliferator activated receptor γcDNA: expression in hematopoietic cells and chromosomal mapping. Gene Expr. 1995;4:281-299.
16. Motojima K, Peters J, Gonzalez F. PPARα mediates peroxisome proliferator-induced transcriptional repression of nonperoxisomal gene expression in mouse. Biochem Biophys Res Commun. 1997;230:155-158.
17. Brun R, Tontonoz P, Forman B, Ellis RJ, Evan R, Spiegelman BM. Differential activation of adipogenesis by multiple PPAR isoforms. Genes Dev. 1996;10:974-984.
18. 2 is a ligand for the adipocyte determination factor PPARγ. Cell. 1995;83:803-812.
19. 2 metabolite binds peroxisome proliferator-activated receptor γ and promotes adipocyte differentiation. Cell. 1995;83:813-819.
20. Nolen J, Ludvik B, Beerdsen P. Improvement in glucose tolerance and insulin resistance in obese subjects treated with troglitazone. N Engl J Med. 1994; 331:1188-1193.
21. Kliewer SA, Sundseth SS, Jones SA, Brown PJ, Wisely GB, Koble CS, Devchand P, Wahli W, Willson TM, Lenhard JM, Lehmann J. Fatty acids and eicosanoids regulate gene expression through direct interactions with the peroxisome proliferator-activated receptor α and γ. Proc Natl Acad Sci U S A. 1997;94:4318-4323.
22. Tontonoz P, Nagy L, Alvarez JG, Thomazy VA, Evans RM. PPARγ promotes monocyte/macrophage differentiation and uptake of oxidized LDL. Cell. 1998;93:241-252.
23. Nagy L, Tontonoz P, Alvarez JG, Chen H, Evans RM. Oxidized LDL regulates macrophage gene expression through ligand activation of PPAR γ. Cell. 1998;93:229-240.
24. Vidal-Puig A, Considine R, Jimenez-Linan M, Werman A, Pories W, Caro J. Flier J. Peroxisome proliferator-activated receptor gene expression in human tissues: effects of obesity, weight loss, and regulation by insulin and glucocorticoids. J Clin Invest. 1997;99:2416-2422.
25. Zhu Y, Qi C, Korenberg J, Chen X, Noya D, Rao M, Reddy J. Structural organization of mouse peroxisome proliferator-activated receptor g (mPPARγ) gene: alternative promotor use and different splicing yield two mPPARg isoforms. Proc Natl Acad Sci U S A. 1995;92:7921-7925.
26. Schoonjans K, Peinado-Onsurbe J, Lefebvre A, Deeb S. Staels B, Auwerx J. PPARα and PPARγ activators direct a distinct tissue-specific transcriptional response via a PPRE in the lipoprotein lipase gene. EMBO J. 1996;15: 5336-5348.
27. Fajas L, Auboeuff D, Raspe E, Schoonjans K, Lefebvre A-M, Saladin R, Najib J, Laville M, Fruchart J.C, Deeb S, Vidal-Puig A, Flier J, Briggs M, Staels B, Vidai H, Auwerx J. The organization, promotor analysis, and expression of the human PPARγ gene. J Biol Chem. 1997;272:18779-18789.
28. Jiang C, Ting A, Seed B. PPAR-γ agonists inhibit production of monocyte inflammatory cytokines. Nature. 1998;391:82-86.
29. Ricote M, Li A, Wilson T, Kelly C, Glass C. The peroxisome proliferator-activated receptor-γ is a negative regulator of macrophage activation. Nature. 1998;391:79-82.
30. Marx N, Sukhova G, Murphy C, Libby P, Plutzky J. Macrophages in human atheroma contain PPARγ: differentiation-dependent PPARγ expression and reduction of MMP-9 activity through PPARγ activation in mononuclear phagocytes. Am J Pathol. 1998;153:17-23.
31. Marx N, Schönbeck U, Lazar MA, Libby P, Plutzky J. Peroxisome proliferator-activated receptor gamma activators inhibit gene expression and migration in human vascular smooth muscle cells. Circ Res. 1998;3: 1097-1103.
32. Schoenbeck U, Mach F, Sukhova G, Murphy C, Bonnefoy J-Y, Fabunmi R, Libby P. Regulation of matrix metalloproteinase expression in human vascular smooth muscle cells by T lymphocytes. Circ Res. 1997;81:448-454.
33. Staels B, Koenig W, Habib A, Merval R, Lebret M, Pineda Torra I, Delerive P, Fadel A, Chinetti G, Fruchart J-C, Najib J, Maclouf J, Tedgui A. Activation of human aortic smooth muscle cells is inhibited by PPARα but not by PPARγ activators. Nature. 1998;393:790-793.
34. Wallon UM, Persson L, Heby O. Regulation of omithine decarboxylase during cell growth: changes in the stability and translatability of the mRNA, and in the turnover of the protein. Mol Cell Biochem. 1995;146:39-44.
35. Shetty S, Kumar A, Idell S. Posttranscriptional regulation of urokinase receptor mRNA: identification of a novel urokinase receptor mRNA binding protein in human mesothelioma cells. Mol Cell Biol. 1997;19:1075-1083.
36. Yu K, Bayona W, Kallen C, Harding H, Ravera C, McMahon G, Brown M, Lazar M. Differential activation of peroxisome proliferator-activated receptors by eicosanoids. J Biol Chem. 1995;270:23975-23983.
37. Latruffe N, Vamecq J. Peroxisome proliferators and peroxisome proliferator activated receptors (PPARs) as regulators for lipid metabolism. Biochimie. 1997;79:81-94.
38. Hu E, Kim J, Sarraf P, Spiegelman BM. Inhibition of adipogenesis through MAP kinase-mediated phosphorylation of PPARγ. Science. 1996;274: 2100-2103.
39. Kim J, Spiegelman BM. ADD1/SREBP1 promotes adipocyte differentiation and gene expression linked to fatty acid metabolism. Genes Dev. 1996;10: 1096-1107.
40. Spiegelman BM. PPARγ in monocytes: less pain, any gain? Cell. 1998;93: 153-155.
41. Lundgren C, Brown S, Nordt T, Sobel B, Fujii S. Elaboration of type-1 plasminogen activator inhibitor from adipocytes: a potential pathogenetic link between obesity and cardiovascular disease. Circulation. 1996;93:106-110.
42. Goldhaber S, Grodstein F, Stampfer M, Manson J, Colditz G, Speizer F, Wilett W, Hennekens C. A prospective study of risk factors for pulmonary embolism in women. JAMA. 1997;277:642-645.
43. Eriksson P, Nilsson L, Karpe F, Hamsten A. Very-low-density lipoprotein response element in the promotor region of the human plasminogen activator inhibitor-1 gene implicated in the impaired fibrinolysis of hypertriglyceridemia. Arterioscler Thromb Vasc Biol. 1998;18:20-26.
44. Ehrmann DA, Schneider DJ, Sobel BE, Cavaghan MK, Imperial J, Rosenfild RL, Polonsky KS. Troglitazone improves defects in insulin action, insulin secretion, ovarian steroidogenesis, and fibronolysis in women with polycystic ovary syndrome. J Clin Endcrinol Metab. 1997;82:2108-2116.